The National Securities and Stock Market Commission (NSSMC) has registered the issue of 2 million bonds of PJSC Pharmaceutical Firm Darnitsa with a total nominal volume of UAH 2 billion. According to the information provided to the disclosure system of the National Securities and Stock Market Commission, the decision to issue registered interest-bearing bonds without a public offering was made by the general meeting of PJSC shareholders.
According to the published data, the bonds are issued in 10 series (from “AA” to “AJ”) with a total nominal value of UAH 200 million each, the maturity and yield have not yet been indicated. The bonds are being placed for the company to further develop. In particular, 60% of the total amount of funds received from the placement of bonds is planned to be used to pay for raw materials and supplies, 30% – to pay for marketing services, 10% – to pay for advertising services.
Earlier, the company issued 1 million bonds also in 10 series for a total nominal amount of UAH 1 billion with maturity on October 1, 2025 and January 1, 2026. Last year’s report indicated that Darnitsa completed the placement of these bonds in 2019. Their rate, indicated in the report, is 30% per year, but the amount of paid interest income is UAH 285.779 million. By the end of 2020, Darnitsa increased its net profit by 33.7% comparing to 2019 – up to UAH 814.994 million. The company’s assets for the year increased by 24.8% – up to UAH 4.3 billion.
Commenting on this news and the global strategy of the corporation’s financial development, Dmytro Shymkiv, the chairman of the Darnitsa Group Board of Directors, said that the management intends to bring the company’s capitalization to USD 1 billion. He clarified that today the company is estimated to cost USD 550-600 million. And currently there are no plans to sell Darnitsa. Lately, the company is considering the prospect of entering the Asian and Latin American markets. The top manager also reminded that “Darnitsa” is the largest EU GMP certified pharmaceutical manufacturer in Ukraine. During 2010-2020, the company invested UAH 1.218 billion in modernization and development of manufacturing. The main task of the company is to provide valuable assistance to medical workers and improve the quality of life of patients through science, innovation and the availability of medicines. According to Shymkiv, “Darnitsa” is successfully coping with its mission, thanks to which it is included in the three most expensive brands in Ukraine according to the “Correspondent” magazine.